Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-446-6 | CAS number: 106-95-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study conducted in compliance with agreed protocols, with no deviations from standard test guidelines and no methodological deficiences, which do not affect the quality of the relevant results. The study report was conclusive, done to a valid guideline and the study was conducted under GLP conditions.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EPA OPPTS 870.5395 (In Vivo Mammalian Cytogenetics Tests: Erythrocyte Micronucleus Assay)
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- 3-bromopropene
- EC Number:
- 203-446-6
- EC Name:
- 3-bromopropene
- Cas Number:
- 106-95-6
- Molecular formula:
- C3H5Br
- IUPAC Name:
- 3-bromoprop-1-ene
- Reference substance name:
- 230-446-6
- IUPAC Name:
- 230-446-6
- Reference substance name:
- 1-bromoprop-2-ene
- IUPAC Name:
- 1-bromoprop-2-ene
- Details on test material:
- Allyl bromide was obtained from Fluka Chemical Corporation (Buchs, Switzerland) in one lot (330638) and from Aldrich Chemical Co. in one lot (03614HN). Lot 330638 was used in the 2-week studies, and lot 03614HN was used in the 40-week studies. Identity and purity analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO) and the study laboratory, BioReliance (Rockville, MD). Reports on analyses performed in support of the allyl bromide studies are on file at the National Institute of Environmental Health Sciences.
Both lots of allyl bromide, a clear, colorless liquid, were identified by the analytical chemistry laboratory using infrared and proton nuclear magnetic resonance (NMR) spectroscopy and by the study laboratory using infrared spectroscopy. All infrared and NMR spectra were consistent with the literature spectra and spectra of a reference standard from the same lot. The purity of each lot was determined by the analytical chemistry and study laboratories using gas chromatography (GC). For lot 330638, GC indicated one major peak and five impurities with a combined peak area of 0.7% relative to the total peak area. GC by a second system indicated one major peak and three impurities with a combined peak area of less than 0.5%. The relative purity was 102% when compared to a reference standard from the same lot. The overall purity of lot 330638 was greater than 99%. For lot 03614HN, GC indicated one major peak and four impurities with a combined peak area of 0.45% relative to the total peak area. GC by a second system indicated one major peak and three impurities with a total combined area less than 0.3% of the total peak area. The relative purity was 102% when compared to a frozen reference from the same lot. The overall purity of lot 03614HN was greater than 99%. During the 40-week studies, additional purity analyses were performed by the study laboratory at 26 weeks and at the end of the study using GC.
To ensure stability, the bulk chemical was stored in a sealed container under a nitrogen headspace, protected from light, at 2° to 8° C. No degradation of the bulk chemical was detected.
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- mouse
- Strain:
- other: FVB/N - C57BL/6 - Tg.AC hemizygous- p53 haploinsufficient mice
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- See paragraphe 7.7
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- Corn oil
- Details on exposure:
- At the end of the 40-week studies of paragraphe 7.7, peripheral blood samples were obtained from male and female mice from each strain. Smears were immediately prepared and fixed in absolute methanol. The methanol-fixed slides were stained with acridine orange and coded. Slides were scanned to determine the frequency of micronuclei in 2,000 normochromatic erythrocytes (NCEs) in each of up to 15 mice per group. In addition, the percentage of polychromatic erythrocytes (PCEs) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity.
- Duration of treatment / exposure:
- 40-week study
- Frequency of treatment:
- Groups of 15 male and 15 female FVB/N and C57BL/6 mice received 0 or 8 mg allyl bromide/kg body weight in corn oil by gavage, in a volume of 10 mL/kg body weight, 5 days per week for 40 weeks. Groups of 15 male and 15 female Tg.AC hemizygous and p53 haploinsufficient mice received 0, 0.5, 1, 2, 4, or 8 mg allyl bromide/kg body weight in 10 mL/kg corn oil by gavage, 5 days per week for 40 weeks. Vehicle control mice received corn oil only.
- Post exposure period:
- None
- No. of animals per sex per dose:
- 15 males and 15 females per group
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Positive control groups of 15 male and 15 female Tg.AC hemizygous mice received dermal applications of 1.25 μg TPA in 100 μL acetone (12.5 μg TPA/L solution), three times per week until removal from study. Positive control mice were removed after the appearance of 20 or more skin papillomas and discarded. The TPA solution was applied to the clipped dorsal skin from the mid-back to the interscapular area.
Examinations
- Tissues and cell types examined:
- Necropsies and microscopic examinations were performed on all mice except positive controls. The heart, right kidney, liver, lung, right testis, and thymus were weighed. At necropsy, all organs and tissues were examined for grossly visible lesions, and all major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 4 to 6 μm, and stained with hematoxylin and eosin for microscopic examination. For all paired organs (e.g., adrenal gland, kidney, ovary), samples from each organ were examined.
- Statistics:
- The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958). Animals found dead of other than natural causes or missing were censored from the survival analyses; animals dying from natural causes were not censored. Statistical analyses for possible dose-related effects on survival used Cox’s (1972) method for testing two groups for equality and Tarone’s (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Negative controls validity:
- valid
- Additional information on results:
- The frequency of micronucleated erythrocytes was assessed in each of the four mouse strains treated with allyl bromide for 40 weeks. Results in all four strains of mice were concluded to be negative; in addition, no significant, consistent changes in the percentage of polychromatic erythrocytes (reticulocytes) among total erythrocytes were observed in any of the four strains.
Some observations of note in these micronucleus tests include the small increase in micronucleated erythrocytes seen in the single dosed group (8 mg/kg) of female C57BL/6 mice that was evaluated for micronucleus frequency. Although the P value was significant (<0.05), these results were judged to be negative because the small increase represented less than half a micronucleus per 1,000 cells, which is not biologically relevant. In the male p53 haploinsufficient mice, one dosed group (1.0 mg/kg) showed a small but significant increase (P=0.0006) in micronucleated erythrocyte frequency, but none of the three higher doses showed an effect; therefore, this small increase at a single dose concentration in one sex, even though statistically significant (P<0.005), was not considered sufficient evidence of the ability of allyl bromide ti induce effect in this assay.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): negative
Not sufficient evidence of the ability of allyl bromide to induce an effect in this assay - Executive summary:
The frequency of micronucleated erythrocytes was assessed in male and female mice for each of the four mouse strains administered allyl bromide by corn oil gavage for 40 weeks. Results in all four micronucleus studies with allyl bromide were concluded to be negative; in addition, no significant changes in the percentage of polychromatic erythrocytes (reticulocytes) among total erythrocytes were observed in any of the four strains of mice.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.